Affinergy Exploring BMP Applications For IFBM Device Coating Process
This article was originally published in The Gray Sheet
Executive Summary
Affinergy's plan to license its Interfacial Biomaterial (IFBM) coating process will allow the start-up to avoid the costs of bringing a combination product to market
You may also be interested in...
Affinergy teams with Synthes
"Biological glue" proprietor Affinergy and orthopedic device manker Synthes will collaborate on multiple product applications across the spine, trauma and craniomaxillofacial markets under a long-term development program announced Sept. 11. Affinergy's Interfacial Biomaterial coating process can reduce the risks of infection, friction and clotting associated with an orthopedic implant, and "provide for a much tighter integration of the actual device," the company says (1"The Gray Sheet" March 8, 2004, p. 26). The firm is interested in targeting the cardiovascular market as well...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.